Sex and gender considerations in Alzheimer's disease: The Women's Brain Project contribution.
Level 5 - mechanism / opinion, no new human data
Narrative review and organizational overview with no primary human data or systematic review methodology.
PubMed 37065460 · doi:10.3389/fnagi.2023.1105620
What was done
This narrative review summarizes existing evidence regarding sex and gender differences in Alzheimer's disease (AD)—spanning epidemiology, physiology, pharmacokinetics, and pharmacodynamics—and describes the contributions and initiatives of the Women's Brain Project (WBP).
What was found
The abstract reports that approximately 131.5 million people worldwide are projected to live with dementia by 2050 and that women represent roughly two-thirds of individuals affected by AD. No original quantitative findings, effect sizes, or new statistical analyses are reported in the abstract.
Why it matters
It highlights sex- and gender-based disparities in Alzheimer's disease burden and outlines organizational and policy frameworks aimed at advancing precision medicine in brain health.
Limits
The work is a narrative overview and organizational summary rather than a systematic review, meta-analysis, or primary clinical investigation. It provides background epidemiological estimates without new empirical data or risk estimates.
Cited by
- supports Two-thirds of the people diagnosed with Alzheimer's disease are women.